import type { SpecialtyMeta } from "../types"

export const meta: SpecialtyMeta = {
  slug: "weight-loss-clinics",
  specialty: "Weight Loss Clinics",
  specialtyLong: "Weight loss and GLP-1 Medical Practices",
  title: "FDA/FTC Compliance Software for Weight Loss & GLP-1 Clinics - RegenCompliance",
  description:
    "Purpose-built compliance scanning for weight loss clinics - especially practices offering GLP-1s and semaglutide. Catches disease claims, compounded-drug marketing issues, and the exact patterns the FDA and FTC are enforcing in 2026.",
  heroBadge: "For weight loss clinics",
  heroTagline:
    "Weight loss - and specifically GLP-1 marketing - is the single highest-growth FDA enforcement category right now. Your marketing needs to be built for 2026 rules, not last year's.",
  riskSummary:
    "Weight loss clinics marketing semaglutide, tirzepatide, and compounded GLP-1s are on the front edge of FDA enforcement in 2026. The FDA has specifically called out compounded GLP-1 marketing, off-label promotion, and brand-identity claims as enforcement priorities. The FTC has precedent going back to the Jenny Craig case on weight-loss testimonial rules. State medical boards scrutinize telehealth-based weight-loss business models in several states. RegenCompliance is built around this exact regulatory surface - not generic healthcare compliance, but the specific phrases and patterns that are getting weight-loss clinics warning letters right now.",
  enforcementExamples: [
    {
      title: "FDA warnings on compounded GLP-1 marketing as brand-equivalent",
      body: "Marketing compounded semaglutide as 'the same as Ozempic' or 'Wegovy at a fraction of the cost' is a specific enforcement target. Compounded versions are legally distinct products and brand-identity claims misrepresent that distinction. Multiple compounding pharmacies and prescribing clinics have received letters in 2025–2026.",
    },
    {
      title: "FTC precedent on weight-loss testimonial disclosure",
      body: "The Jenny Craig, Nutrisystem, and POM Wonderful cases established that weight-loss before/after and outcome claims require the strongest typical-experience disclosures of any healthcare category. 'Results not typical' is insufficient; the disclosure must reflect actual average outcomes, not peak outcomes.",
    },
    {
      title: "State medical board actions on telehealth-first weight loss models",
      body: "Several states have taken action against weight-loss clinics operating telehealth-first models that imply prescribing without a full standard-of-care examination. Marketing language that emphasizes speed and convenience over clinical evaluation has been cited as part of the enforcement basis.",
    },
    {
      title: "FDA letters on 'FDA-approved for weight loss' claims on off-label treatments",
      body: "Marketing a medication as 'FDA-approved for weight loss' when the approval is for a different indication (e.g., semaglutide approved as Ozempic for type 2 diabetes but marketed as a weight-loss product without referencing the Wegovy labeling) has produced multiple warning letters.",
    },
  ],
  bannedPhrases: [
    {
      phrase: "Same as Ozempic",
      why: "Brand-identity claim on a compounded product misrepresents legal distinction. FDA enforcement priority in 2026.",
      alternative: "Compounded semaglutide - a separate medication prepared by a licensed compounding pharmacy",
      risk: "HIGH",
    },
    {
      phrase: "Guaranteed 20 pounds in 30 days",
      why: "Specific quantified guarantee is rarely substantiable and runs into FTC weight-loss-specific rules.",
      alternative: "Most patients on our program report [range] of weight loss over [timeframe]; individual results vary",
      risk: "HIGH",
    },
    {
      phrase: "FDA-approved for weight loss",
      why: "Whether a specific medication is FDA-approved for weight loss depends on indication. Misuse of 'FDA-approved' is a top enforcement pattern.",
      alternative: "FDA-approved for [specific labeled indication] and prescribed by our providers based on clinical evaluation",
      risk: "HIGH",
    },
    {
      phrase: "No diet, no exercise required",
      why: "Absolute claim conflicts with label indications for virtually all weight-loss medications, which require concurrent diet and activity modification.",
      alternative: "Medically supervised weight loss that works alongside your lifestyle - diet and activity guidance included",
      risk: "HIGH",
    },
    {
      phrase: "Reverses obesity",
      why: "Disease-state reversal language crosses the drug-claim threshold for weight-loss medications.",
      alternative: "Helps many patients achieve clinically meaningful weight loss when combined with lifestyle changes",
      risk: "HIGH",
    },
    {
      phrase: "Cheaper than the brand-name version",
      why: "Comparative price claim based on brand equivalence misrepresents that compounded is a distinct product.",
      alternative: "Our compounded options may be more affordable for cash-pay patients than brand-name equivalents - pricing discussed at consultation",
      risk: "MEDIUM",
    },
    {
      phrase: "Proven to work",
      why: "Unsubstantiated efficacy claim; requires citation to clinical evidence that matches your specific protocol.",
      alternative: "Clinical studies of semaglutide in patients meeting [criteria] have shown [specific outcome] - your results depend on your situation",
      risk: "MEDIUM",
    },
    {
      phrase: "Rapid results in weeks",
      why: "Time-frame claim that conflicts with label data (most significant loss occurs over months, not weeks).",
      alternative: "Most patients see measurable progress within their first few months on the program",
      risk: "MEDIUM",
    },
    {
      phrase: "No side effects",
      why: "Absolute safety claim conflicts with GLP-1 prescribing information.",
      alternative: "Most patients tolerate the medication well; common side effects are reviewed during your consultation",
      risk: "HIGH",
    },
    {
      phrase: "Get your script today",
      why: "Implies prescribing without meaningful clinical evaluation; state medical board enforcement pattern.",
      alternative: "Schedule a medical evaluation today - if you are a candidate, treatment can begin [timeframe]",
      risk: "MEDIUM",
    },
    {
      phrase: "Cures type 2 diabetes",
      why: "Disease cure claim on a disease-management medication.",
      alternative: "Supports blood sugar management as part of a comprehensive treatment plan",
      risk: "HIGH",
    },
    {
      phrase: "Celebrity-approved",
      why: "Implied endorsement without FTC-required material-connection disclosure.",
      alternative: "(Remove entirely unless you have a documented paid endorser with required disclosures)",
      risk: "HIGH",
    },
  ],
  commonCatches: [
    {
      title: "Homepage headlines framing weight loss as a guaranteed outcome",
      body: "'Lose up to 20 lbs in your first month' is the single most common weight-loss homepage headline - and one of the most commonly cited in enforcement. Our scanner catches the pattern and suggests compliant alternatives that still convert.",
    },
    {
      title: "Instagram posts with outcome captions and no typical-experience disclosure",
      body: "Weight-loss is the category where typical-experience rules are strictest, and Instagram is where they are most consistently violated. The scanner flags the missing disclosure and generates the exact language to insert.",
    },
    {
      title: "Compounded-vs-brand equivalence language",
      body: "Any language framing compounded semaglutide as equivalent to Ozempic or Wegovy - 'same active ingredient,' 'same as,' 'identical to' - is a current FDA target. Our scanner flags all common phrasings.",
    },
    {
      title: "Patient testimonials with peak-outcome framing",
      body: "'Lost 60 pounds in 6 months' without typical-experience context is the exact testimonial structure the Jenny Craig case targeted. Our scanner catches peak-outcome patterns and suggests disclosure language.",
    },
    {
      title: "Ad copy promising fast turnaround from intake to prescription",
      body: "State medical boards target marketing that minimizes the clinical evaluation step. 'Approved in 24 hours,' 'script same day,' 'skip the doctor visit' are all common flags.",
    },
  ],
  caseStudy: {
    title: "A typical first scan on a GLP-1 weight loss clinic homepage",
    before:
      "Our compounded semaglutide is the same as Ozempic at a fraction of the cost - guaranteed 20 pounds in 30 days with no diet, no exercise, no side effects. FDA-approved for weight loss, celebrity-approved, proven to work. Get your script today.",
    after:
      "Our compounded semaglutide is a distinct medication prepared by a licensed compounding pharmacy - pricing discussed at consultation. Most patients on our program report meaningful weight loss over their first several months; individual results vary. Our providers prescribe based on clinical evaluation of each patient's medical history and goals. Most patients tolerate the medication well; common side effects and candidacy are reviewed during your consultation.",
    outcome:
      "Score went from 12 to 91 across 11 flagged phrases. PDF audit trail generated. No core value proposition removed - every marketing message translated into a compliant framing that holds up under current FDA/FTC enforcement.",
  },
  uniqueValue:
    "Weight loss - especially GLP-1 marketing - is the most actively-enforced healthcare marketing category in 2026. The specific patterns the FDA is targeting (brand-equivalence language on compounded products, off-label efficacy claims, FDA-approved misuse) require a rule set that was updated last week, not last year. Our ingestion pipeline adds new enforcement actions to the rule set within 24 hours. That freshness is not a nice-to-have for weight-loss clinics - it is the difference between being protected and being a lagging indicator.",
  whoThisIsFor: [
    "Telehealth weight-loss practices",
    "GLP-1-focused medical clinics",
    "Compounding pharmacies marketing to end consumers",
    "Bariatric medical practices",
    "Integrative/functional medicine weight loss practices",
    "Primary-care-adjacent weight-loss programs",
    "Med spa weight-loss divisions",
  ],
  faqs: [
    {
      q: "Is compounded semaglutide marketing legal?",
      a: "Compounding itself is a regulated pharmacy practice, and compounded GLP-1 prescribing is legal when done within the rules. Marketing it is where most clinics run into trouble - brand-equivalence language ('same as Ozempic'), off-label efficacy claims, and inadequate disclosure of the distinction between compounded and brand-name products are all current FDA enforcement targets. Our scanner is specifically trained on the compliant framings that preserve the marketing message without triggering the enforcement pattern.",
    },
    {
      q: "What is the FTC typical-experience rule for weight loss?",
      a: "The FTC Endorsement Guides require that testimonials and before/after claims reflect generally expected results, not peak outcomes. For weight loss specifically, the standard is stricter than for other categories due to precedent from the Jenny Craig, Nutrisystem, and POM Wonderful enforcement cases. Our scanner catches peak-outcome testimonials and inserts the specific disclosure language the FTC has accepted in similar contexts.",
    },
    {
      q: "What about off-label GLP-1 use for weight loss when prescribing Ozempic?",
      a: "Off-label prescribing itself is common and legal. Marketing off-label is where it gets complicated - marketing Ozempic as a weight-loss drug (its on-label indication is type 2 diabetes) raises the same issues as marketing any medication outside its approved labeling. Our scanner flags the distinction and suggests framings that acknowledge the clinical reality without making off-label promotional claims.",
    },
    {
      q: "Do state medical boards care about my marketing?",
      a: "Yes - particularly for telehealth weight-loss models. Several state medical boards have explicitly stated that marketing emphasizing speed-over-clinical-evaluation is a factor in enforcement. 'Script in 24 hours,' 'skip the doctor visit,' and similar patterns are flagged by our scanner because they are specifically what state boards have cited.",
    },
    {
      q: "Can I still do before/after photos?",
      a: "Yes, with proper disclosures and the right framing. The photo itself is less of an issue than the caption, surrounding copy, and typical-experience disclosure. Our scanner does not analyze the image but it does analyze all the text around it - and it flags the specific patterns that have triggered FTC action (missing disclosures, peak-outcome framing, unrepresentative selection language).",
    },
    {
      q: "What if I partner with a compounding pharmacy?",
      a: "Many clinics do. The partnership is fine; the marketing is where the risk sits - specifically, how you describe the compounded product to patients. Our scanner flags brand-equivalence and equivalence-pricing language that has triggered FDA letters. The compliant framings it suggests preserve your ability to offer the service while avoiding the specific phrasings under enforcement.",
    },
    {
      q: "How often is your weight-loss rule set updated?",
      a: "Daily. Weight-loss enforcement is moving faster than any other healthcare category right now, and a static rule set from even six months ago would miss several of the current target patterns. Our ingestion pipeline adds new FDA warning letters and FTC press releases to the rule set within 24 hours of publication.",
    },
    {
      q: "Do I still need a healthcare marketing attorney?",
      a: "Yes, particularly for this specialty. Weight loss is an active-enforcement area and any close-call language should involve counsel. Our scanner handles the high-volume pattern-matching work - the part attorney review cannot feasibly do per-item at their billing rate. Most weight-loss practices using both together reduce their attorney spend on routine review and spend those hours on strategic calls (telehealth model structure, compounding partnership, prescription workflow) where judgment matters.",
    },
  ],
  relatedBlogSlugs: [
    "glp-1-semaglutide-marketing-compliance",
    "healthcare-testimonial-compliance",
    "banned-words-healthcare-marketing-2026",
  ],
  keywords: [
    "weight loss clinic compliance software",
    "GLP-1 marketing compliance",
    "semaglutide marketing FDA",
    "compounded GLP-1 marketing rules",
    "weight loss clinic FTC compliance",
    "telehealth weight loss marketing",
    "Ozempic marketing compliance",
  ],
}
